

InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Wednesday, May 29, 2024

written by InvestorNews | May 28, 2024

InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Wednesday, May 29th, at 9 AM EST, featuring Brent Willis, the President, CEO, and Director of [Voyageur Pharmaceuticals Ltd.](#) (TSXV: VM). To participate in this engaging discussion, please [click here](#)

Currently, Voyageur Pharmaceuticals holds [138,881,576](#) shares outstanding and has a market capitalization of [CAD\\$6,249,671](#).

In preparation for tomorrow's InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review:


- May 28, 2024 – Voyageur Pharmaceuticals Ltd Secures USD \$1.9 Million Sales Contract for SmoothX 2% Barium Contrast – [click here](#)
- April 3, 2024 – Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors – [click here](#)
- March 26, 2024 – Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options – [click here](#)

5-Data Points from Voyageur's most recent news release on May 28, 2024, titled, *Voyageur Pharmaceuticals Ltd Secures USD \$1.9*

Million Sales Contract for SmoothX 2% Barium Contrast:

- **Sales Contract Value:** Voyageur Pharmaceuticals has secured a sales contract valued at USD \$1.9 million (CAD \$2.6 million) for the first three years of commercialization of their SmoothX 2% barium contrast medium.
- **International Expansion:** This contract marks the company's first international distribution agreement, targeting the radiology product market in Latin America and involving marketing and sales rights in two countries.
- **Expansion into U.S. Market:** Voyageur plans to expand into the U.S. market, leveraging regulatory approvals and successes in other countries to introduce its innovative imaging products.
- **Future Product Line:** Voyageur has four additional barium sulfate contrast medium products at late stages of development, which include high-density and low-density solutions for various gastrointestinal radiographic examinations.
- **Corporate Strategy and Commitment:** Voyageur is planning to expand into the U.S. market and aims to become a vertically integrated, carbon-neutral company in the radiology contrast media drug market, emphasizing sustainability and cost efficiency.

(05.28.2024 at 12:00 PM EST, [Source](#))



For more information on Voyager Pharmaceuticals Ltd., [click here](#).

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.